These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2148992)

  • 1. The immune response of low dose recombinant DNA hepatitis B vaccine in teenagers in Singapore.
    Guan R; Tay HH; Yap I; Smith R; Tan LH
    Trans R Soc Trop Med Hyg; 1990; 84(5):731-2. PubMed ID: 2148992
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children.
    Milne A; Moyes CD; Allwood GK; Pearce NE; Krugman S
    N Z Med J; 1988 Feb; 101(840):67-9. PubMed ID: 2967940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of low doses of recombinant hepatitis B vaccine in young males.
    Tsakalakis C; Richardson SC; Roumeliotou-Karayannis A; Papaevangelou G
    Vaccine; 1988 Aug; 6(4):328-30. PubMed ID: 2973188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine.
    Just M; Berger R; Scheiermann N
    Vaccine; 1988 Oct; 6(5):401-2. PubMed ID: 2973694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients.
    Bruguera M; Rodicio JL; Alcazar JM; Oliver A; Del Rio G; Esteban-Mur R
    Vaccine; 1990 Mar; 8 Suppl():S47-9; discussion S60-2. PubMed ID: 2139283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response to hepatitis B vaccine in premature neonates.
    Chawareewong S; Jirapongsa A; Lokaphadhana K
    Southeast Asian J Trop Med Public Health; 1991 Mar; 22(1):39-40. PubMed ID: 1835140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates.
    Gunn TR; Bosley A; Woodfield DG
    N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody response after intradermal administration of recombinant hepatitis B vaccine in children.
    Wiström J; Gustafsson A
    Scand J Infect Dis; 1990; 22(5):621-2. PubMed ID: 2148015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a recombinant hepatitis B vaccine in patients infected with Schistosoma mansoni.
    Bassily S; Hyams KC; el-Ghorab N; el-Masry NA
    Am J Trop Med Hyg; 1990 May; 42(5):449-52. PubMed ID: 2140243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intradermal hepatitis B immunization with yeast-derived vaccine: serological response by sex and age.
    Morris CA; Oliver PR; Reynolds F; Selkon JB
    Epidemiol Infect; 1989 Oct; 103(2):387-94. PubMed ID: 2530104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of an anti-hepatitis-B vaccination in a population at risk].
    Stellato M; Carbi S; Tosolini S
    Boll Ist Sieroter Milan; 1989; 68(1):34-41. PubMed ID: 2535244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules.
    Scheiermann N; Gesemann M; Maurer C; Just M; Berger R
    Vaccine; 1990 Mar; 8 Suppl():S44-6; discussion S60-2. PubMed ID: 2139282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inadequate immune response among public safety workers receiving intradermal vaccination against hepatitis B--United States, 1990-1991.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1991 Aug; 40(33):569-72. PubMed ID: 1830921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness and tolerance of genetically engineered vaccines for hepatitis B--a comparative study].
    Schmid K; Strebl H; Heck KJ; Weltle D; Raithel HJ
    Gesundheitswesen; 1992 May; 54(5):219-22. PubMed ID: 1535816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune response to hepatitis B vaccine produced with genetic engineering].
    Ramón Torrell JM; Micheo Salas C; Cerdó Goicouria C; Casas García I; Escribá Jordana JM
    Rev Clin Esp; 1991 Feb; 188(2):68-71. PubMed ID: 2041902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down's syndrome.
    Van Damme P; Vranckx R; Meheus A
    Vaccine; 1990 Mar; 8 Suppl():S53-5; discussion S60-2. PubMed ID: 2139285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and efficacy of anti-hepatitis B vaccines in hemodialysis patients.
    Dentico P; Volpe A; Buongiorno R; Maracchione N; Carbone M; Manno C; Proscia F
    Nephron; 1992; 61(3):324-5. PubMed ID: 1386904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men.
    Odaka N; Eldred L; Cohn S; Muñoz A; Fields HA; Fox R; Solomon R; Kaslow R; Polk BF
    JAMA; 1988 Dec 23-30; 260(24):3635-7. PubMed ID: 2973531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus infection among Swedish adults: aspects on seroepidemiology, transmission, and vaccine response.
    Struve J
    Scand J Infect Dis Suppl; 1992; 82():1-57. PubMed ID: 1386474
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of low-dose intradermal hepatitis B vaccine.
    Rajadhyaksha KP; Haridas V; Plumber ST; Pipalia DH; Kamat RS; Abraham P; Naik SR
    Indian J Gastroenterol; 1988 Apr; 7(2):111. PubMed ID: 2966112
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.